๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Dresden
Clinical trial register · Germany

Clinical Trials in Dresden, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 28 Dresden 14 Frankfurt 13 Hamburg 12 Ulm 11
Narrow the registerReset
Recruitment status
Phase
Site location
Berlin28 Dresden14 Frankfurt13 Hamburg12 Ulm11
All 89 locations
Target enrolment
to

Trials with a site in Dresden

14 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07225569Hidradenitis Suppurativa
Sanofi
Phase 2
144
Blankenfelde-Mahlow, Darmstadt, Dresden, Merzig, Regensburg, Rostock
2025-12-29
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931Crohn's Disease
Sanofi
Phase 3
980
Tรผbingen, Ulm, Wรผrzburg, Remscheid, Ludwigshafen am Rhein, Dresden, Leipzig, Jerichow
2025-10-01
Recruiting
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
NCT07088068Type 1 Diabetes Mellitus
Sanofi
Phase 3
723
Augsburg, Bielefeld, Dresden, Frankfurt, Freiburg im Breisgau, Hanover, Leipzig, Munich
2025-08-06
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360Chronic Rhinosinusitis With Nasal Polyps
Sanofi
Phase 3
216
Dresden, Hamburg, Leipzig, Mainz, Villingen-Schwenningen
2025-02-06
Recruiting
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
NCT06500702Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
Sanofi
Phase 2
84
Berlin, Dresden, Hanover
2024-12-19
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Sanofi
Phase 3
2,500
Bayreuth, Berlin, Bochum, Dresden, Dรผsseldorf, Essen, Giessen, Hamburg
2024-04-16
Active, closed
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891Chronic Graft Versus Host Disease
Sanofi
Phase 3
260
Berlin, Cologne, Dresden, Freiburg im Breisgau, Hamburg, Kiel, Mรผnster, Regensburg
2024-01-23
Active, closed
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486Multiple Sclerosis
Sanofi
Phase 3
943
Bielefeld, Bochum, Dresden, Dรผsseldorf, Erbach im Odenwald, Essen, Heidelberg, Jena
2023-12-27
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
Sanofi
Phase 3
1,655
Bielefeld, Bochum, Bรถblingen, Dresden, Dรผsseldorf, Erbach im Odenwald, Essen, Giessen
2023-12-13
Active, closed
Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)
NCT06111586Type 1 Diabetes Mellitus
Sanofi
Phase 2
197
Dresden, Hanover, Oldenburg in Holstein, Ulm
2023-12-11
Active, closed
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT05769777Dermatitis Atopic
Sanofi
Phase 2
999
Augsburg, Bad Bentheim, Berlin, Dresden, Mรผnster, Osnabrรผck, Rostock, Witten
2023-04-03
Active, closed
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578Dermatitis Atopic
Sanofi
Phase 2/3
1,856
Augsburg, Bad Bentheim, Berlin, Blankenfelde-Mahlow, Dresden, Gera, Hamburg, Kiel
2022-08-22
Active, closed
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
NCT05405166Plasma Cell Myeloma Recurrent
Sanofi
Phase 3
531
Dresden, Heidelberg, Lรผbeck, Nuremberg
2022-06-23
Rows per page Showing 1–14 of 14
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/dresden

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 14 of those studies with a site in Dresden that also match the filters currently applied.

How many clinical trials are recruiting in Dresden?

4 of the 14 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 0 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Dresden), 14 studies
PhaseStudiesRecruitingShare
Phase 39264.3%
Phase 24228.6%
Phase 2/3107.1%

Most active sponsors

Lead sponsors with the most studies (Dresden)
Lead sponsorStudiesRecruiting
Sanofi144
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.